je.st
news
Tag: gilead
3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year
2015-03-01 17:35:43| Biotech - Topix.net
Revlimid was already on pace to deliver sales of more than $5 billion this year as the leading second-line treatment for the indication; the FDA and EU's approval for its use in newly diagnosed patients could mean that sales finish 2015 closer to an annualized $6 billion pace than a $5 billion pace. Celgene should also be able to notch solid sales growth from its third-line multiple myeloma drug Pomalyst and its cancer drug Abraxane.
Gilead dodges billions in taxes as money rolls in from hepatitis C drugs
2015-02-26 23:21:38| Biotech - Topix.net
Gilead Sciences, whose $1,000-a-pill hepatitis C treatment is one of the world's most expensive drugs, is avoiding billions of dollars in U.S. taxes by booking profits overseas. The Foster City company reported foreign income before taxes of $8.2 billion for 2014, earning more in non-U.S. profits than it recorded in non-U.S. sales.
Gilead Sciences to Present at the RBC Capital Markets 2015 Healthcare...
2015-02-25 02:41:00| Biotech - Topix.net
Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the RBC Capital Markets 2015 Healthcare Conference in New York. Robin Washington, Gilead's Executive Vice President and Chief Financial Officer, will provide an overview of the company at the conference on Wednesday, February 25 at 8:30 a.m. Eastern Time.
Tags: present
capital
sciences
markets
Mylan, Gilead in deal for Hepatitis C medications in India
2015-02-23 14:58:16| Biotech - Topix.net
Mylan Pharmaceuticals Private Ltd., the Indian subsidiary of Mylan , reached the agreement to distribute Gilead Sciences' Sovaldi and Harvoni. It expects to start marketing the branded medication in the second quarter.
Tags: in
deal
india
medications
1 Number Shows Why Gilead Sciences, Inc. Shareholders Should Be Thrilled Right Now
2015-02-15 09:56:54| Biotech - Topix.net
In fact, these numbers are so impressive that I'm going to reel off a few them: Those are envy-inspiring results, but out of all of Gilead Sciences numbers, there is one number that stands apart in showing why this company is poised to remain a biotechnology mainstay for years to come. What is this most-important number? Dominating indications Before I dig a bit deeper into how Gilead Sciences racked up this jaw-dropping earnings growth, let's begin with a quick refresher on the company.
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »